Steven C. Quay, M.D., Ph.D., of Atossa Genetics Elected as a Fellow of the College of American Pathologists
March 14, 2011 08:00 ET | Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - March 14, 2011) - Atossa Genetics, Inc., a privately-held health care company focused on the development and marketing of novel cellular and molecular diagnostic risk...
MolecularMD Corp. Obtains Exclusive License From NYU and MSKCC for BRAF Melanoma Assay
October 18, 2010 07:00 ET | MolecularMD
PORTLAND, OR--(Marketwire - October 18, 2010) - MolecularMD Corp. announced today that it has entered into a licensing agreement with New York University (NYU) and Memorial Sloan-Kettering Cancer...
Atossa Genetics, Inc. Announces Filing of S-1 Registration Statement
October 01, 2010 09:30 ET | Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - October 1, 2010) - Atossa Genetics, Inc., a privately-held healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk...
Atossa Genetics, Inc. Appoints Edward Sauter, M.D., Ph.D., to Its Scientific Advisory Board
February 25, 2010 11:00 ET | Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - February 25, 2010) -  Atossa Genetics, Inc., a privately-held healthcare company focused on the development and marketing of novel cellular and molecular diagnostic...
Atossa Genetics, Inc. Launches Corporate Web Site Featuring New FDA-Approved Breast Cancer Risk Assessment Test
February 08, 2010 08:30 ET | Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - February 8, 2010) - Atossa Genetics, Inc., a privately-held healthcare company focused on the development and marketing of novel cellular and molecular diagnostic...
MolecularMD Establishes New Operations Facility to Support Growth in Personalized Cancer Medicine Business
October 28, 2009 07:00 ET | MolecularMD
PORTLAND, OR--(Marketwire - October 28, 2009) - MolecularMD Corp announced today that it has moved their core operations to a expanded dedicated facility with capacity and functionality to support...